X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM syndrome

Cambridge, MA – May 17, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-RD, the company’s CXCR4 antagonist, has been selected for poster presentation at the 23 rd Annual Congress of the European Hematology Association (EHA), taking place June 14-17 in Stockholm, Sweden. The presentation will describe interim clinical results from the ongoing Phase 2/3 study of X4P-001-RD in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease.

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »